Abeona Therapeutics Inc. (NASDAQ:ABEO) Stock Has Average Target Price of $21.00

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) have received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $21.00.

A number of equities analysts have recently commented on ABEO shares. HC Wainwright reaffirmed a “buy” rating on shares of Abeona Therapeutics in a report on Friday, September 25th. UBS Group reiterated a “buy” rating on shares of Abeona Therapeutics in a research report on Friday, September 25th. Weiss Ratings cut shares of Abeona Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, August 17th. Roth Capital assumed coverage on shares of Abeona Therapeutics in a research report on Thursday, September 17th. They set a “buy” rating and a $17.00 price objective on the stock. Finally, Cantor Fitzgerald lifted their price objective on shares of Abeona Therapeutics from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, September 18th.

Insider Buying and Selling at Abeona Therapeutics

In other news, CEO Vishwas Seshadri sold 19,608 shares of the stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total transaction of $101,177.28. Following the completion of the sale, the chief executive officer owned 1,286,500 shares in the company, valued at approximately $6,638,340. This represents a 1.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mark Alvino sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $5.86, for a total value of $87,900.00. Following the transaction, the director directly owned 62,065 shares in the company, valued at approximately $363,700.90. This represents a 19.46% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 55,428 shares of company stock valued at $296,508. Corporate insiders own 7.10% of the company’s stock.

Institutional Trading of Abeona Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ABEO. Royal Bank of Canada increased its stake in Abeona Therapeutics by 49.6% in the 1st quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 2,155 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Abeona Therapeutics in the 1st quarter worth $154,000. WINTON GROUP Ltd acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter worth $256,000. Rangeley Capital LLC lifted its stake in shares of Abeona Therapeutics by 4.2% in the 1st quarter. Rangeley Capital LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $269,000 after acquiring an additional 2,400 shares during the period. Finally, Pale Fire Capital SE boosted its holdings in shares of Abeona Therapeutics by 17.3% in the second quarter. Pale Fire Capital SE now owns 81,945 shares of the biopharmaceutical company’s stock valued at $506,000 after acquiring an additional 12,100 shares in the last quarter. 80.56% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Stock Down 0.5%

Shares of NASDAQ ABEO opened at $4.41 on Tuesday. The business has a 50-day moving average price of $5.59 and a 200 day moving average price of $5.75. The stock has a market cap of $252.16 million, a PE ratio of -4.05 and a beta of 1.31. The company has a quick ratio of 6.40, a current ratio of 6.63 and a debt-to-equity ratio of 0.01. Abeona Therapeutics has a 52-week low of $4.00 and a 52-week high of $7.65.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.12). The business had revenue of $11.38 million during the quarter, compared to the consensus estimate of $12.24 million. Equities research analysts forecast that Abeona Therapeutics will post -0.88 earnings per share for the current year.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a biotechnology company focused on developing and commercializing cell and gene therapies for serious diseases. The company’s primary focus is regenerative medicine, with an emphasis on treatments that address rare genetic disorders and conditions involving damaged or absent tissue.

Abeona’s lead product, ZEVASKYN (prademagene zamikeracel, formerly EB-101), is an autologous, gene-corrected cell therapy for wounds associated with recessive dystrophic epidermolysis bullosa (RDEB).